CN101301275A - 含烟碱的口服剂量形式的制备方法 - Google Patents

含烟碱的口服剂量形式的制备方法 Download PDF

Info

Publication number
CN101301275A
CN101301275A CNA2008101253651A CN200810125365A CN101301275A CN 101301275 A CN101301275 A CN 101301275A CN A2008101253651 A CNA2008101253651 A CN A2008101253651A CN 200810125365 A CN200810125365 A CN 200810125365A CN 101301275 A CN101301275 A CN 101301275A
Authority
CN
China
Prior art keywords
nicotine
active substance
lozenge
dosage form
melt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2008101253651A
Other languages
English (en)
Chinese (zh)
Inventor
J·刘
S·J·莱赫
S·普拉特考
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CN101301275A publication Critical patent/CN101301275A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNA2008101253651A 2001-03-26 2002-03-22 含烟碱的口服剂量形式的制备方法 Pending CN101301275A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27860601P 2001-03-26 2001-03-26
US60/278606 2001-03-26

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA028073339A Division CN1553771A (zh) 2001-03-26 2002-03-22 含烟碱的口服剂量形式

Publications (1)

Publication Number Publication Date
CN101301275A true CN101301275A (zh) 2008-11-12

Family

ID=23065632

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA028073339A Pending CN1553771A (zh) 2001-03-26 2002-03-22 含烟碱的口服剂量形式
CNA2008101253651A Pending CN101301275A (zh) 2001-03-26 2002-03-22 含烟碱的口服剂量形式的制备方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNA028073339A Pending CN1553771A (zh) 2001-03-26 2002-03-22 含烟碱的口服剂量形式

Country Status (11)

Country Link
EP (1) EP1372392A4 (enrdf_load_stackoverflow)
JP (1) JP2004525928A (enrdf_load_stackoverflow)
CN (2) CN1553771A (enrdf_load_stackoverflow)
AR (1) AR033444A1 (enrdf_load_stackoverflow)
AU (1) AU2002252470B2 (enrdf_load_stackoverflow)
BR (1) BR0208382A (enrdf_load_stackoverflow)
CA (1) CA2440713A1 (enrdf_load_stackoverflow)
MX (1) MXPA03008762A (enrdf_load_stackoverflow)
NZ (1) NZ528167A (enrdf_load_stackoverflow)
PL (1) PL364621A1 (enrdf_load_stackoverflow)
WO (1) WO2002076211A1 (enrdf_load_stackoverflow)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104132895A (zh) * 2014-07-08 2014-11-05 国家烟草质量监督检验中心 适用于连续流动法测定烟草及烟草制品中总植物碱的缓冲体系
CN104363768A (zh) * 2012-04-17 2015-02-18 R.J.雷诺兹烟草公司 重熔的可摄取产品
CN115003281A (zh) * 2020-01-15 2022-09-02 麦克内尔股份公司 锭剂

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253307A1 (en) * 2003-02-04 2004-12-16 Brian Hague Sugar-free oral transmucosal solid dosage forms and uses thereof
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
PL2446881T3 (pl) * 2003-07-24 2014-08-29 Glaxosmithkline Llc Folie rozpuszczające się w jamie ustnej
GB0320854D0 (en) 2003-09-05 2003-10-08 Arrow No 7 Ltd Buccal drug delivery
US20070191815A1 (en) 2004-09-13 2007-08-16 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
AU2004289248B2 (en) 2003-11-07 2012-05-03 U.S. Smokeless Tobacco Company Llc Tobacco compositions
RU2351148C2 (ru) * 2004-08-11 2009-04-10 КЭДБЕРИ АДАМС ЮЭсЭй ЭлЭлСи Согревающие композиции и системы их доставки
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
WO2008069921A2 (en) * 2006-12-01 2008-06-12 Cima Labs Inc. Oral transmucosal nicotine dosage form
GB2468424B (en) * 2007-04-02 2011-11-09 Parkinson S Inst Methods and compositions for reduction of side effects of therapeutic treatments
ES2521494T3 (es) 2007-04-02 2014-11-12 Parkinson's Institute Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos
DE102008012015A1 (de) 2008-03-01 2009-09-10 Südzucker AG Mannheim/Ochsenfurt Verbesserte Isomalt-haltige Komprimate und Verfahren zu ihrer Herstellung
CN102770138B (zh) * 2010-02-18 2015-12-09 J·V·达卡 含有尼古丁的软凝胶锭剂
US20110274628A1 (en) * 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
UA112974C2 (uk) * 2010-09-16 2016-11-25 Джеі. Бі. Кемікалс Енд Фармасьютікалс Лімітид Нікотиновмісна композиція (варіанти)
CA2841785A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
US9474303B2 (en) * 2011-09-22 2016-10-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9629392B2 (en) 2011-09-22 2017-04-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9084439B2 (en) 2011-09-22 2015-07-21 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US20130078307A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
US9907748B2 (en) 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
TW201507726A (zh) * 2013-05-10 2015-03-01 Glaxosmithkline Llc 菸鹼菱形錠配製物
WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
CA2977814A1 (en) 2015-03-12 2016-09-15 Chrono Therapeutics Inc. Craving input and support system
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
SE541358C2 (en) * 2017-05-30 2019-08-13 Enorama Pharma Ab Nicotine-containing chewing gum compositions
AU2019279884B2 (en) 2018-05-29 2025-01-30 Morningside Venture Investments Limited Drug delivery methods and systems
MA54245A (fr) 2018-11-16 2022-02-23 Morningside Venture Investments Ltd Système d'administration transdermique de médicaments à régulation thermique
WO2020244725A1 (en) * 2019-06-07 2020-12-10 Ncp Nextgen A/S Nicotine pouch product
USD1081739S1 (en) 2021-04-06 2025-07-01 Altria Client Services Llc Die for gum forming
US20220313678A1 (en) * 2021-04-06 2022-10-06 Altria Client Services Llc Spray dried nicotine for inclusion in oral products
US12295412B2 (en) 2022-01-28 2025-05-13 Altria Client Services Llc Oral pouch product

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
US5549906A (en) * 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
US5362496A (en) * 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
DE19536394A1 (de) * 1995-09-29 1997-04-03 Basf Ag Feste Arzneiformen, erhältlich durch Extrusion einer Isomalt enthaltenden Polymer-Wirkstoff-Schmelze
DE19639342C2 (de) * 1996-09-25 1998-07-16 Suedzucker Ag Kaugummi, enthaltend ein Süßungsmittel
US6322806B1 (en) * 1999-04-06 2001-11-27 Wm. Wrigley Jr. Company Over-coated chewing gum formulations including tableted center

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104363768A (zh) * 2012-04-17 2015-02-18 R.J.雷诺兹烟草公司 重熔的可摄取产品
JP2015516153A (ja) * 2012-04-17 2015-06-11 アール・ジエイ・レイノルズ・タバコ・カンパニー 再融解摂取製品
CN104363768B (zh) * 2012-04-17 2018-03-16 R.J.雷诺兹烟草公司 重熔的可摄取产品
US10517818B2 (en) 2012-04-17 2019-12-31 R.J. Reynolds Tobacco Company Remelted ingestible products
CN104132895A (zh) * 2014-07-08 2014-11-05 国家烟草质量监督检验中心 适用于连续流动法测定烟草及烟草制品中总植物碱的缓冲体系
CN104132895B (zh) * 2014-07-08 2017-08-25 国家烟草质量监督检验中心 适用于连续流动法测定烟草及烟草制品中总植物碱的缓冲体系
CN115003281A (zh) * 2020-01-15 2022-09-02 麦克内尔股份公司 锭剂

Also Published As

Publication number Publication date
PL364621A1 (en) 2004-12-13
AU2002252470B2 (en) 2008-05-22
BR0208382A (pt) 2004-06-15
CN1553771A (zh) 2004-12-08
WO2002076211A1 (en) 2002-10-03
NZ528167A (en) 2005-04-29
EP1372392A1 (en) 2004-01-02
AR033444A1 (es) 2003-12-17
CA2440713A1 (en) 2002-10-03
MXPA03008762A (es) 2004-02-18
EP1372392A4 (en) 2004-06-23
JP2004525928A (ja) 2004-08-26

Similar Documents

Publication Publication Date Title
CN101301275A (zh) 含烟碱的口服剂量形式的制备方法
US20040101543A1 (en) Nicotine-containing oral dosage form
AU2003267268B2 (en) Modified release oral dosage form
AU2002252470A1 (en) Nicotine-containing oral dosage form
CA2028931C (en) Hard confections containing hydrogenated isomaltulose and a medicinally active ingredient
CN102186461A (zh) 多部分口腔内剂型及其用途
US20110014132A1 (en) Solid effervescent mixture for the oral absorption
JP3357618B2 (ja) ニコチン含有刺激製剤
KR20100017820A (ko) 아미노산으로 완충된 경구 니코틴 제형
TW200810755A (en) New product and use and manufacture thereof
KR20100020476A (ko) 아미노산으로 완충된 코팅된 경구 니코틴 제형
CN101843581A (zh) 具有器官感觉特性的多部分口腔内剂型
CN104053433A (zh) 具有减少的感官干扰的含尼古丁固体剂型
IL159425A (en) Gum that contains nicotine, ways to make and use it
AU2010201229A1 (en) Multi-portion intra-oral dosage form with organoleptic properties
Kumar et al. Medicated chewing gum-a novel drug delivery system: An updated review
CN102309689A (zh) 天麻咀嚼胶剂及其制备及检测方法
AU2008202048A1 (en) Nicotine-containing oral dosage form
JUNO et al. PHARMACEUTICAL SCIENCES

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20081112